


THE PROBLEM



Allergic rhinitis

- Chronic respiratory system disease
- Causes sneezing, congestion, itching and runny nose
- Comorbidities: asthma, dermatitis and polyp formation



OUR SOLUTION




- ✓ A single medicine to relieve allergic rhinitis
- ✓ Relief without discomfort
- ✓ Friendly administration




MARKET




FOUNDING TEAM



Dra. Sonia Mayra Pérez Tapia
Executive Director, UDIBI
Specialist in innovation, development, evaluation and regulation of biotechnological products for human use. Collaborator of COFEPRIS in regulation of innovative biotechnological products and cell therapies. Founder and CEO of UDIBI of the IPN.



Dr. Juan Carlos Almagro
Deputy Director, UDIBI
Expert in antibody engineering and development of biological therapies. With more than 25 years of experience in the pharmaceutical industry. Antibody development at Pfizer and Jansen. Founder and CEO of GBI.



Dr. Luis Alberto Vallejo Castillo
Research, Development and Innovation, UDIBI
Specialist in bioequivalence studies, biocomparability and development of biotherapeutic products at the preclinical level.

INVESMENT

Stage 1 Fundraising

USD \$4,000,000

Financing the cash deficit for the growth plan for the next 18 months of operation.

In the next 18 months

- MoA Efficacy**
Characterization
- Pk/Pd**
Laboratories in security studies
- Safety**
Development of GMP manufacturing method

First round Preclinical studies efficacy/MoA	USD 4,000,000 (26.6%)
Phase I with manufacturing of clinical material	USD 3,000,000 (20.0%)
Clinical phase II and III	USD 8,000,000 (53.4%)

Contact:
Francisco Lozano Martínez
flozano@newgenesis.cl

Raúl Vázquez Cassani
rvazquez@newgenesis.cl